Russia Unveils First-Ever Drug for Ankylosing Spondylitis After 20 Years of Research

Russia has launched the world's first drug designed to treat ankylosing spondylitis, a chronic inflammatory disease. The medication, named Seniprutug, was officially registered in 2024 after nearly two decades of development. It targets the cartilage in spinal joints, where the condition causes persistent pain and stiffness.

Ankylosing spondylitis typically affects people under 40, leading to reduced mobility and long-term discomfort. The disease progresses by inflaming the spine and other joints, often worsening over time.

Development of Seniprutug began in 2005, with one of its lead researchers, Sergei Lukyanov, personally battling the condition. His firsthand experience shaped the drug's creation. By 2026, the medication had advanced through Phase II trials, with Phase III now underway involving over 600 participants.

Though not yet approved by major regulators like the EMA or FDA, more than 50 patients have already received Seniprutug outside formal trials. The drug remains under investigation, with no official global authorisation as of February 2026.

Seniprutug marks a significant step in treating ankylosing spondylitis, offering hope for patients with limited options. Clinical trials continue to assess its safety and effectiveness. For now, its use remains restricted to research settings and a small group of early recipients.